Dr. Goldsmith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1405 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-785-1112Fax+1 404-785-6288
Education & Training
- Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005
- Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2002
- University of Alabama School of MedicineClass of 1999
Certifications & Licensure
- GA State Medical License 2009 - 2025
- PA State Medical License 2000 - 2010
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
- MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- 30 citationsRandomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji
Journal of Clinical Oncology. 2021-07-16 - 20 citationsA phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.Muna Qayed, Thomas Cash, Mourad Tighiouart, Tobey J. MacDonald, Kelly C. Goldsmith
Pediatric Blood & Cancer. 2020-04-01 - 52 citationsPhase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid
Clinical Cancer Research. 2018-12-15
Press Mentions
- Clinical Trial May Change the Paradigm of Care for Patients with ALK-Driven High-Risk NeuroblastomaApril 4th, 2023
- Researchers Show Lorlatinib Is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk NeuroblastomaMarch 31st, 2023
- Targeted Cancer Treatment Helps Georgia Boy Facing Advanced NeuroblastomaOctober 5th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: